From GlobeNewswire: 2024-11-29 20:40:00

Rakovina Therapeutics Inc. announced its financial results for Q3 2024, reporting a net loss of $1,015,667 for the quarter ending September 30, 2024. The company highlighted advancements in AI technology and collaborations with Variational AI to enhance drug discovery for cancer therapies. Additionally, Rakovina presented research findings at prestigious conferences in Spain and the US.

The partnership with Variational AI provides Rakovina exclusive rights to compounds tailored for specific target profiles. AI platforms like Deep Docking have accelerated drug discovery, with results achieved in less than five months. Presentations at prominent conferences showcased promising PARP inhibitor compounds with the potential to treat neurological cancers by crossing the blood-brain barrier.

Rakovina Therapeutics recently announced a non-brokered private placement financing of units priced at $0.06 per unit, totaling $1.25 million. Due to high investor demand, the offering was increased to $2.5 million. The company’s financial statements for Q3 2024 revealed a net loss of $2,588,630 for the nine months ending September 30, 2024.

To provide further insights, Rakovina Therapeutics will host an information and update webinar on December 4, 2024. The company focuses on developing innovative cancer treatments using AI-powered technologies targeting the DNA-damage response. With a pipeline of unique inhibitors, Rakovina aims to advance drug candidates into human clinical trials in collaboration with pharmaceutical partners.

For more information on Rakovina Therapeutics Inc. and its initiatives, visit their website at www.rakovinatherapeutics.com. The TSXV has not approved or disapproved the content of this press release. Forward-looking statements regarding the company’s business plan and operations are subject to risk factors and uncertainties that may impact actual results. Investors are advised to review the company’s filings on SEDAR for comprehensive risk factor disclosure.



Read more at GlobeNewswire:: Rakovina Therapeutics Announces 2024 Q3 Financial Results